Cargando…

A Randomized Pilot Study of the Effect of Trelagliptin and Alogliptin on Glycemic Variability in Patients with Type 2 Diabetes

INTRODUCTION: This open-label, parallel-group, exploratory study examined the effects of two dipeptidyl peptidase 4 (DPP4) inhibitors on glycemic variability (GV) in patients with type 2 diabetes. METHODS: Randomized patients with glycated hemoglobin A1c of at least 6.5% to less than 8.5% received t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishimura, Rimei, Osonoi, Takeshi, Koike, Yasuhiro, Miyata, Kouji, Shimasaki, Yukio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822803/ https://www.ncbi.nlm.nih.gov/pubmed/31562608 http://dx.doi.org/10.1007/s12325-019-01097-z

Ejemplares similares

Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry
por: Inagaki, Nobuya, et al.
Publicado: (2014)

Effect of Trelagliptin on Quality of Life in Patients with Type 2 Diabetes Mellitus: Study Protocol
por: Ishii, Hitoshi, et al.
Publicado: (2017)

Effect of the FreeStyle Libre™ flash glucose monitoring system on glycemic control in individuals with type 2 diabetes treated with basal–bolus insulin therapy: An open label, prospective, multicenter trial in Japan
por: Ogawa, Wataru, et al.
Publicado: (2020)

Effect of Hemodialysis on Plasma Glucose Profile and Plasma Level of Liraglutide in Patients with Type 2 Diabetes Mellitus and End-Stage Renal Disease: A Pilot Study
por: Osonoi, Takeshi, et al.
Publicado: (2014)

Which is better, high‐dose metformin monotherapy or low‐dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy? A randomized, cross‐over, continuous glucose monitoring‐based pilot study
por: Takahashi, Hiroshi, et al.
Publicado: (2018)

Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148
por: Mita, Tomoya, et al.
Publicado: (2017)

Alogliptin benzoate for management of type 2 diabetes
por: Saisho, Yoshifumi
Publicado: (2015)

Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor
por: Ishii, Hitoshi, et al.
Publicado: (2019)

Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: an extension of the SPEAD-A study
por: Mita, Tomoya, et al.
Publicado: (2023)

Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study
por: Nishimura, Rimei, et al.
Publicado: (2019)

Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study
por: Ida, Satoshi, et al.
Publicado: (2016)

Long-Term Effect of Alogliptin on Glycemic Control in Japanese Patients With Type 2 Diabetes: A 3.5-Year Observational Study
por: Takebayashi, Kohzo, et al.
Publicado: (2017)

Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry)
por: Ueki, Kohjiro, et al.
Publicado: (2021)

Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: Results from a randomized, Phase IV study
por: Kaku, Kohei, et al.
Publicado: (2018)

Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
por: Kim, Hae Jin, et al.
Publicado: (2022)

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
por: DeFronzo, Ralph A., et al.
Publicado: (2008)

Suitability of various chromatographic and spectroscopic techniques for analysis and kinetic degradation study of trelagliptin
por: Zaghary, Wafaa A., et al.
Publicado: (2017)

Different Spectrophotometric Methods for Simultaneous Determination of Trelagliptin and Its Acid Degradation Product
por: Mowaka, Shereen, et al.
Publicado: (2018)

Efficacy and Patient Satisfaction of the Weekly DPP-4 Inhibitors Trelagliptin and Omarigliptin in 80 Japanese Patients with Type 2 Diabetes
por: Tosaki, Takahiro, et al.
Publicado: (2017)

Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index
por: Aoki, Chie, et al.
Publicado: (2017)

Investigation of Alogliptin-Loaded In Situ Gel Implants by 2(3) Factorial Design with Glycemic Assessment in Rats
por: Ibrahim, Tarek M., et al.
Publicado: (2022)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holland, Daniel Q, et al.
Publicado: (2014)

Effects of metformin and alogliptin on body composition in people with type 2 diabetes
por: Takeshita, Yumie, et al.
Publicado: (2018)

Efficacy and Safety of Alogliptin in Elderly Patients With Type 2 Diabetes Mellitus
por: Takeda, Hiroshi, et al.
Publicado: (2019)

Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
por: Kaku, Kohei, et al.
Publicado: (2019)

24-Hour Glycemic Variations in Drug-Naïve Patients with Type 2 Diabetes: A Continuous Glucose Monitoring (CGM)-Based Study
por: Ando, Kiyotaka, et al.
Publicado: (2013)

Biphasic insulin aspart‐30 reduces glycemic variability to a greater degree than insulin detemir: A randomized controlled trial of once‐daily insulin regimens using continuous glucose monitoring
por: Tsujino, Daisuke, et al.
Publicado: (2017)

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
por: Capuano, Annalisa, et al.
Publicado: (2013)

The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus
por: Dudkowski, Caroline, et al.
Publicado: (2016)

Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies
por: Berhan, Asres, et al.
Publicado: (2013)

Efficacy of ipragliflozin as monotherapy or as add‐on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics
por: Osonoi, Takeshi, et al.
Publicado: (2017)

Immunohistochemical Pharmacokinetics of the Anti-diabetes Drug Alogliptin in Rat Kidney and Liver
por: Yamamoto, Yutaro, et al.
Publicado: (2020)

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
por: Triplitt, Curtis, et al.
Publicado: (2010)

Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2010)

Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study
por: Takeda, Hiroshi, et al.
Publicado: (2016)

A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes
por: Shigematsu, Erina, et al.
Publicado: (2017)

Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end‐stage renal disease: Results from a randomized, phase 3 study
por: Kaku, Kohei, et al.
Publicado: (2019)

Treatment of Streptozotocin-Induced Diabetic Rats with Alogliptin: Effect on Vascular and Neural Complications
por: Davidson, Eric P., et al.
Publicado: (2011)

Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin
por: Wang, Hongyu, et al.
Publicado: (2015)

Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients
por: Kurozumi, Akira, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_busioree71eednv0tml145keeq